Crystal structure of aprocitentan Form A, C 16 H 14 Br 2 N 6 O 4 S
Source abstract
Abstract
Abstract The crystal structure of aprocitentan Form A has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Aprocitentan Form A crystallizes in space group P-1 (#2) with a = 11.7381(11), b = 10.6771(12), c = 9.6624(5) Å, α = 110.4365(13), β = 92.3143(13), γ = 113.513 (2)°, V = 1,017.53(5) Å 3 , and Z = 2 at 298 K. The crystal structure consists of layers of aprocitentan molecules, approximately along the 1,-7,7 plane. N–H···N hydrogen bonds link the molecules within these layers. The powder pattern has been submitted to the International Centre for Diffraction Data for inclusion in the Powder Diffraction File™.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystal structures of chemical compounds · X-ray Diffraction in Crystallography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. 2024
2. 10.1021/ar00172a00510.1021/ar00172a005 ↗
3. 10.1063/1.46788210.1063/1.467882 ↗
4. Chen, M. , and Zhu, H. . 2021. “Crystal Form of Aprocitentan, Preparation Method Therefor and Use Thereof.” International Patent Application WO 2021/088645 A1.
5. Bolli, M. , Boss, C. , and Treiber, A. . 2012. “4-Pyrimidinesulfamide Derivative.” U.S. Patent US 8324232 B2.
6. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
7. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
8. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
9. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
10. 10.1002/jcc.2315310.1002/jcc.23153 ↗
11. Bolli, M. , Kohler, P. , Schindelholz, I. , and Von Raumer, M. . 2020. “Crystalline Forms of a 4-Pyrimidinesulfamide Derivative Aprocitentan.” U.S. Patent Application US 2020/0002317 A1.
12. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
13. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
14. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
15. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
16. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
17. 10.1016/j.chphi.2022.10014710.1016/j.chphi.2022.100147 ↗
18. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
19. Bolli, M. , Kohler, P. , Schindelholz, I. , and Von Raumer, M. . 2018. “Crystalline Forms of the 4-Pyrimidinesulfamide Derivative Aprocitentan.” International Patent Application WO 2018/154101 A1.
20. 2013
21. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
22. Bibulić, P. and Matećić, M. . 2021. “Solid State Forms of Aprocitentan and Process for Preparation Thereof.” International Patent Application WO 2021/237004 A1.
23. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
24. Bravais · 1866
25. 10.1002/anie.19951555110.1002/anie.199515551 ↗
26. 2024
27. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
28. 2023
29. Putz · 2023
30. A New Law of Crystal Morphology Extending the Law of Bravais
31. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
32. 2023
33. 10.1021/ci049780b10.1021/ci049780b ↗
34. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
35. 10.1007/BF0054909610.1007/BF00549096 ↗